Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer

CTLA-4+Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis

(2015) Hyun-Bae Jie et al.   CANCER RESEARCH

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

(2015) N. A. Giraldo et al.   CLINICAL CANCER RESEARCH

Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection

(2015) Shohei Eto et al.   Gastric Cancer

Deregulation of Immune Response Genes in Patients With Epstein-Barr Virus-Associated Gastric Cancer and Outcomes

(2015) Sun Young Kim et al.   GASTROENTEROLOGY

Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer

(2015) Yi Qing et al.   Drug Design Development and Therapy

The Coordinated Actions of TIM-3 on Cancer and Myeloid Cells in the Regulation of Tumorigenicity and Clinical Prognosis in Clear Cell Renal Cell Carcinomas

(2015) Y. Komohara et al.   Cancer Immunology Research

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

(2014) Jin Won Kim et al.   Gastric Cancer

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer

(2013) Raoul A. Droeser et al.   EUROPEAN JOURNAL OF CANCER

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

(2012) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma

(2011) Jocelyne Jacquemier et al.   INTERNATIONAL JOURNAL OF CANCER

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

(2010) Ryosuke Hino et al.   CANCER

Systemic Immune Tuning in Renal Cell Carcinoma

(2010) Antonia Busse et al.   JOURNAL OF IMMUNOTHERAPY

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer

(2009) Yan-Fang Gao et al.   Journal of Translational Medicine

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

(2008) Paul Salama et al.   JOURNAL OF CLINICAL ONCOLOGY